SEK36.4 -1.0 -2.7%
Last Trade - 03/03/21
| Market Cap | £90.5m |
| Enterprise Value | £76.8m |
| Revenue | £37.6k |
| Position in Universe | 913th / 1857 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 30th Apr | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.46 | 2.43 | 0.63 | 2.72 | 3.01 | 1.67 | 2.00 | 39.0 | +29.5% | ||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates with numerous institutions, such as Karolinska Institutet in Sweden and Dana Farber Cancer Institute, Washington University, Baylor College of Medicine, City of Hope Research & Treatment Center in the Unites States, as well as The International Breast Cancer Study Group (IBCSG) based in Switzerland and Breast International Group in Belgium.
| Last Annual | April 30th, 2020 |
| Last Interim | October 31st, 2020 |
| Public Since | March 29, 2017 |
| No. of Shareholders: | n/a |
| No. of Employees: | 21 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange | OMX Nordic Exchange Stockholm |
| Shares in Issue | 28,273,372 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Uppsala Science Park, UPPSALA, 752 37, Sweden |
| Web | http://biovica.com/ |
| Phone | +46 18 4444830 |
| Contact | Anders Rylander (Chief Executive Officer, Director) |
| Auditors | Grant Thornton Sweden AB |
As of 03/03/21, shares in Biovica International AB are trading at SEK36.4, giving the company a market capitalisation of £90.5m. This share price information is delayed by 15 minutes.
Shares in Biovica International AB are currently trading at SEK36.4 and the price has moved by 0.153k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Biovica International AB price has moved by 0.137k% over the past year.
Of the analysts with advisory recommendations for Biovica International AB, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Biovica International AB is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Biovica International AB is scheduled to issue upcoming financial results on the following dates:
Biovica International AB does not currently pay a dividend.
Biovica International AB does not currently pay a dividend.
Biovica International AB does not currently pay a dividend.
To buy shares in Biovica International AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Biovica International AB are currently trading at SEK36.4, giving the company a market capitalisation of £90.5m.
Here are the trading details for Biovica International AB:
Based on an overall assessment of its quality, value and momentum, Biovica International AB is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Biovica International AB are currently priced at SEK36.4. At that level they are trading at 35.83% premium to the analyst consensus target price of 0.00.
Analysts covering Biovica International AB currently have a consensus Earnings Per Share (EPS) forecast of -1.35 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biovica International AB. Over the past six months, the relative strength of its shares against the market has been 6.64%. At the current price of SEK36.4, shares in Biovica International AB are trading at 7.32% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Biovica International AB.
Biovica International AB's management team is headed by:
Here are the top five shareholders of Biovica International AB based on the size of their shareholding:
